Astria Therapeutics (NASDAQ:ATXS) Earns Buy Rating from HC Wainwright

Astria Therapeutics (NASDAQ:ATXS)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Thursday,Benzinga reports. They presently have a $16.00 price target on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 70.76% from the company’s previous close.

A number of other equities research analysts also recently weighed in on the stock. Wedbush reiterated an “outperform” rating and set a $22.00 price target on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Evercore ISI upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. TD Cowen started coverage on shares of Astria Therapeutics in a research note on Monday, July 29th. They set a “buy” rating and a $35.00 price target on the stock. Finally, Oppenheimer lifted their price target on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Astria Therapeutics currently has an average rating of “Buy” and an average price target of $25.60.

Astria Therapeutics Trading Down 7.1 %

Shares of ATXS stock opened at $9.37 on Thursday. Astria Therapeutics has a 1 year low of $4.26 and a 1 year high of $16.90. The firm’s fifty day simple moving average is $11.40 and its 200 day simple moving average is $10.61. The firm has a market capitalization of $528.66 million, a P/E ratio of -4.48 and a beta of 0.71.

Institutional Investors Weigh In On Astria Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Astria Therapeutics by 23.4% in the 1st quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock valued at $35,693,000 after purchasing an additional 480,184 shares in the last quarter. Tidal Investments LLC acquired a new stake in shares of Astria Therapeutics in the 1st quarter valued at $1,664,000. Sofinnova Investments Inc. acquired a new stake in shares of Astria Therapeutics in the 2nd quarter valued at $552,000. ClariVest Asset Management LLC acquired a new position in Astria Therapeutics during the 2nd quarter worth about $731,000. Finally, Ameritas Investment Partners Inc. lifted its position in Astria Therapeutics by 135.6% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock worth $70,000 after buying an additional 2,861 shares in the last quarter. Institutional investors and hedge funds own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.